Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

470.69 +1.75 (+0.37%)
Streaming Delayed Price Updated: 11:44 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,526
Open 469.48
Bid (Size) 469.81 (40)
Ask (Size) 470.70 (200)
Prev. Close 468.94
Today's Range 466.81 - 474.45
52wk Range 266.98 - 519.99
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
From United Therapeutics Corporation
Via Business Wire

Performance

YTD
-5.2%
-5.2%
1 Month
-7.2%
-7.2%
3 Month
+11.8%
+11.8%
6 Month
+57.9%
+57.9%
1 Year
+27.4%
+27.4%

More News

Read More
News headline image
3 Market-Beating Stocks to Target This Week
Via StockStory
Topics Credit Cards Supply Chain
News headline image
Investment Advisor Doubles Down on Insurance Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Bonds Regulatory Compliance
News headline image
Nepsis Bets on CAVA's Future Growth Plan With $2.9 Million Purchase ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Cash-Heavy Stocks to Target This Week and 1 We Question
Via StockStory
News headline image
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
Via StockStory
Topics Artificial Intelligence
News headline image
Why a $27 Million Buy Signals New Confidence in Weatherford Stock ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Value Investing Case Study ↗
Via Chartmill
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Caviar Cruise Quality Investment ↗
Via Chartmill
News headline image
2 Mooning Stocks on Our Buy List and 1 That Underwhelm
Via StockStory
News headline image
Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
3 Reasons Investors Love United Therapeutics (UTHR)
Via StockStory
News headline image
Is United Therapeutics Corp Gaining or Losing Market Support? ↗
Via Benzinga
News headline image
P/E Ratio Insights for United Therapeutics ↗
Via Benzinga
News headline image
My Top Vanguard Index ETF Pick for 2026 ↗
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
The 5 Most Interesting Analyst Questions From United Therapeutics’s Q3 Earnings Call
Via StockStory
Topics Earnings Intellectual Property
News headline image
If You Invested $100 In United Therapeutics Stock 5 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
United Therapeutics Corporation to Present at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
From United Therapeutics Corporation
Via Business Wire

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 470.69
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 01/26/26 11:44 AM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 21.13B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 21B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.